US-based biopharmaceutical firm AzurRx BioPharma has agreed to acquire clinical-stage biotechnology company First Wave Bio in a stock-and-cash deal valued at $229m.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,